Emavusertib (CA-4948) (C09-0881-011)

InformationEmavusertib (CA-4948) Emavusertib (CA-4948) is a potent and orally bioavailable inhibitor of interleukin-1 receptor-associated kinase 4/FMS-like Tyrosine Kinase 3 (IRAK4/FLT3) with anti-tumor activity.TargetsIRAK4 ; FLT3In vitroEmavusertib (CA-4948) is over 500-fold more selective for IRAK-4 compared to IRAK-1. Emavusertib (CA-4948) reduces TNF-α, IL-1β, IL-6 and IL-8 release from TLR-Stimulated THP-1 Cells with an IC50 <250 nM. Emavusertib (CA-4948) has antiproliferative activity due to inhibition of receptor-type tyrosine-protein kinase FLT3.In vivoEmavusertib (CA-4948) has anti-tumour activity in animal models including tumours containing MyD88 gene mutations.Cell Research(from reference)Cell lines：THP-1 cells Concentrations：0.1 μM-10 μM Incubation Time：60 min. Specification: 0.99 Molecular Formula: C24H25N7O5 Molecular Weight: 491.5 PubChem CID: 118224491 Isomeric SMILES: CC1=NC=CC(=C1)C2=NC(=CO2)C(=O)NC3=CC4=C(N=C3N5CC[C@H](C5)O)N=C(O4)N6CCOCC6 Related Documents: https://ald-pub-files.oss-cn-shanghai.aliyuncs.com/aladdinsci/pdp/sds/1/E414483-SCI_11e6d33f586598df8d30fadc00cd62fd.pdf